Genetic changes in nonepithelial ovarian cancer

Nonepithelial ovarian cancers (OCs), including sex cord-stromal tumors (SCSTs) and germ cell tumors (GCTs), are an uncommon subset of OC, together accounting for 10% of all OCs. The etiology of these tumors remains largely unresolved. It is well established that tumorigenesis is the result of multiple genetic alterations driving a normal cell toward a malignant state. Much effort has been made into researching the molecular mechanisms underlying epithelial OC, but far less is known about the genetic changes in SCSTs and GCTs. Recently, a single point missense mutation (C134W) was found in the FOXL2 gene in approximately 95% of adult-type granulosa cell tumors, suggesting a key role for FOXL2 in these tumors. By contrast, the FOXL2 mutation was not found in the juvenile type. DICER1 somatic missense mutations were found in approximately 60% of Sertoli-Leydig tumors. Ovarian GCTs share many morphological features and a similar pattern of chromosomal alterations with testicular GCTs. In the latter, recent genome-wide association studies have identified seven susceptibility loci near KITLG, SPRY4, UKC2, BAK1, DMRT1, TERT and ATF7IP. All of the susceptibility loci detected thus far are all involved in primordial germ cell function or sex determination. TGF-β/BMP and Wnt/β-catenin signaling was absent in dysgerminomas, but present in yolk sac tumors, suggesting intertumoral heterogeneity. In this article, the authors aim to provide an overview of the current knowledge on the possible molecular changes in SCSTs and GCTs of the ovary.

[1]  M. Pike,et al.  Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. , 2013, Human molecular genetics.

[2]  B. Benayoun,et al.  Adult ovarian granulosa cell tumor transcriptomics: prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation , 2013, Oncogene.

[3]  M. Morgan,et al.  Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. , 2013, The Lancet. Oncology.

[4]  R. Coleman,et al.  Investigational agents in development for the treatment of ovarian cancer , 2013, Investigational New Drugs.

[5]  S. Chu,et al.  Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells. , 2013, Molecular endocrinology.

[6]  J. Parma,et al.  Leydig cell tumors in children: contrasting clinical, hormonal, anatomical, and molecular characteristics in boys and girls. , 2012, The Journal of pediatrics.

[7]  A. Shelling,et al.  The Transcriptional Targets of Mutant FOXL2 in Granulosa Cell Tumours , 2012, PloS one.

[8]  J. Kigawa,et al.  Clinical trials and future potential of targeted therapy for ovarian cancer , 2012, International Journal of Clinical Oncology.

[9]  D. Armstrong,et al.  Role of farletuzumab in epithelial ovarian carcinoma. , 2012, Current pharmaceutical design.

[10]  S. Pangas Bone morphogenetic protein signaling transcription factor (SMAD) function in granulosa cells , 2012, Molecular and Cellular Endocrinology.

[11]  D. Bowtell,et al.  The changing view of high-grade serous ovarian cancer. , 2012, Cancer research.

[12]  W. Sellers,et al.  Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations , 2012, Molecular Cancer Therapeutics.

[13]  D. Gershenson Treatment of ovarian cancer in young women. , 2012, Clinical obstetrics and gynecology.

[14]  A. J. Hooten,et al.  Associations between variants in KITLG, SPRY4, BAK1, and DMRT1 and pediatric germ cell tumors , 2012, Genes, chromosomes & cancer.

[15]  B. Karlan,et al.  Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Steven J. M. Jones,et al.  Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. , 2012, The New England journal of medicine.

[17]  P. Fuller,et al.  Molecular pathogenesis of granulosa cell tumors of the ovary. , 2012, Endocrine reviews.

[18]  K. Podratz,et al.  Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: Brief report and review of the literature , 2012, The journal of obstetrics and gynaecology research.

[19]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Bast,et al.  Molecular approaches to personalizing management of ovarian cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  H. Earl,et al.  Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Barshack,et al.  FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors. , 2011, Gynecologic oncology.

[23]  M. Hung,et al.  Deciphering the role of forkhead transcription factors in cancer therapy. , 2011, Current drug targets.

[24]  D. Rakheja,et al.  Bone morphogenetic protein signalling activity distinguishes histological subsets of paediatric germ cell tumours. , 2011, International journal of andrology.

[25]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[26]  R. Montironi,et al.  KIT gene mutation and amplification in dysgerminoma of the ovary , 2011, Cancer.

[27]  Kangseok Lee,et al.  Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W) , 2011, Oncogene.

[28]  D. Huntsman,et al.  FOXL2 Is a Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary , 2011, The American journal of surgical pathology.

[29]  M. Friedlander,et al.  The Role of Hormonal Therapy in Gynecological Cancers-Current Status and Future Directions , 2011, International Journal of Gynecologic Cancer.

[30]  Stephen L. Abrams,et al.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health , 2011, Oncotarget.

[31]  Melissa J. Davis,et al.  Nuclear Receptor Profiling of Ovarian Granulosa Cell Tumors , 2011, Hormones & cancer.

[32]  A. Oza,et al.  A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  E. Simpson,et al.  Aromatase Is a Direct Target of FOXL2: C134W in Granulosa Cell Tumors via a Single Highly Conserved Binding Site in the Ovarian Specific Promoter , 2010, PloS one.

[34]  R. Broaddus,et al.  A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma , 2010, Cancer.

[35]  Jason D. Wright,et al.  Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report. , 2010, Anticancer research.

[36]  R. Butzow,et al.  The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary , 2010, Modern Pathology.

[37]  M. Friedlander,et al.  A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. , 2010, Gynecologic oncology.

[38]  A. Mutirangura,et al.  Targeted therapies for rare gynaecological cancers. , 2010, The Lancet. Oncology.

[39]  Deborah Hughes,et al.  Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer , 2010, Nature Genetics.

[40]  N. Yoo,et al.  Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers , 2010, The Journal of pathology.

[41]  I Vergote,et al.  The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. , 2010, Gynecologic oncology.

[42]  Anton J. Enright,et al.  Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. , 2010, Cancer research.

[43]  A. Gartel A new target for proteasome inhibitors: FoxM1 , 2010, Expert opinion on investigational drugs.

[44]  R. Lovell-Badge,et al.  Somatic Sex Reprogramming of Adult Ovaries to Testes by FOXL2 Ablation , 2009, Cell.

[45]  Ryan D. Morin,et al.  Mutation of FOXL2 in granulosa-cell tumors of the ovary. , 2009, The New England journal of medicine.

[46]  S. Rubin,et al.  A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. , 2009, Gynecologic oncology.

[47]  A. Sood,et al.  Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. , 2009, Gynecologic oncology.

[48]  M. Greene,et al.  A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome. , 2009, Cancer epidemiology.

[49]  Deborah Hughes,et al.  A genome-wide association study of testicular germ cell tumor , 2009, Nature Genetics.

[50]  J. Baselga,et al.  Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  S. Chu,et al.  Proteasome Inhibition by Bortezomib Decreases Proliferation and Increases Apoptosis in Ovarian Granulosa Cell Tumors , 2009, Reproductive Sciences.

[52]  P. Fuller,et al.  Expression Status and Mutational Analysis of the PTEN and P13K Subunit Genes in Ovarian Granulosa Cell Tumors , 2009, International Journal of Gynecologic Cancer.

[53]  S. Chu,et al.  Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. , 2009, Molecular endocrinology.

[54]  E. Fridman,et al.  Promising Effect of Aromatase Inhibitors on Recurrent Granulosa Cell Tumors , 2009, International Journal of Gynecologic Cancer.

[55]  P. Mhawech-Fauceglia,et al.  The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. , 2008, Gynecologic oncology.

[56]  Pier Paolo Pandolfi,et al.  The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.

[57]  B. Vanderhyden,et al.  Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  J. Sebolt-Leopold,et al.  Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway , 2008, Clinical Cancer Research.

[59]  Hans Skovgaard Poulsen,et al.  Mechanisms for oncogenic activation of the epidermal growth factor receptor. , 2007, Cellular signalling.

[60]  N. Colombo,et al.  Management of ovarian stromal cell tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Fellous,et al.  Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children. , 2007, Fertility and sterility.

[62]  R. Lothe,et al.  Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers , 2007, Molecular Cancer.

[63]  S. Modesitt,et al.  Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases. , 2006, Gynecologic oncology.

[64]  Phil G Knight,et al.  TGF-beta superfamily members and ovarian follicle development. , 2006, Reproduction.

[65]  C. Patte,et al.  Activating mutations of the stimulatory g protein in juvenile ovarian granulosa cell tumors: a new prognostic factor? , 2006, The Journal of clinical endocrinology and metabolism.

[66]  Liang Cheng,et al.  Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis , 2006, Modern Pathology.

[67]  H. Denk,et al.  Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study. , 2006, Gynecologic oncology.

[68]  M. Fritsch,et al.  Activation of Wnt/β-Catenin Signaling in Distinct Histologic Subtypes of Human Germ Cell Tumors , 2006 .

[69]  M. Stratton,et al.  Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. , 2006, Human molecular genetics.

[70]  J. Amy,et al.  GnRH antagonist in the adjuvant treatment of a recurrent ovarian granulosa cell tumor: a case report. , 2005, Gynecologic oncology.

[71]  Liang Cheng,et al.  Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications , 2005, Modern Pathology.

[72]  C. Tzeng,et al.  Molecular cytogenetics of ovarian granulosa cell tumors by comparative genomic hybridization. , 2005, Gynecologic oncology.

[73]  J. Bell,et al.  Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. , 2005, Gynecologic oncology.

[74]  Y. Nishi,et al.  Transrepression of Estrogen Receptor Signaling by Nuclear Factor-B in Ovarian Granulosa Cells , 2004 .

[75]  D. Schlessinger,et al.  Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. , 2004, Human molecular genetics.

[76]  S. Chu,et al.  Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours , 2004, Trends in Endocrinology & Metabolism.

[77]  Mark P. de Caestecker,et al.  The transforming growth factor-beta superfamily of receptors. , 2004, Cytokine & growth factor reviews.

[78]  D. Schlessinger,et al.  The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome , 2001, Nature Genetics.

[79]  G. Firestone,et al.  Follicle-Stimulating hormone (FSH) stimulates phosphorylation and activation of protein kinase B (PKB/Akt) and serum and glucocorticoid-lnduced kinase (Sgk): evidence for A kinase-independent signaling by FSH in granulosa cells. , 2000, Molecular endocrinology.

[80]  R. Lothe,et al.  DNA copy number changes in malignant ovarian germ cell tumors. , 2000, Cancer research.

[81]  S. Chu,et al.  Comment on analysis of mutations in genes of the follicle-stimulating hormone receptor in ovarian granulosa cell tumors. , 1999, The Journal of clinical endocrinology and metabolism.

[82]  H. Burger,et al.  Inhibin subunit gene expression in ovarian cancer. , 1999, Gynecologic oncology.

[83]  R. Scully,et al.  Absence of mutations in the FSH receptor in ovarian granulosa cell tumors. , 1998, The Journal of clinical endocrinology and metabolism.

[84]  R. Sutherland,et al.  Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40. , 1998, Cancer research.

[85]  N. Pavlidis,et al.  Megestrol activity in recurrent adult type granulosa cell tumour of the ovary. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  R. Scully,et al.  A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors. , 1997, The Journal of clinical endocrinology and metabolism.

[87]  C. L. Edwards,et al.  Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. , 1996, The Journal of reproductive medicine.

[88]  E. Kawasaki,et al.  Two G protein oncogenes in human endocrine tumors. , 1990, Science.

[89]  H. Burger,et al.  Inhibin as a marker for granulosa-cell tumors. , 1989, The New England journal of medicine.

[90]  A. Talerman Germ cell tumors of the ovary. , 1987, Current opinion in obstetrics & gynecology.

[91]  I. Vergote,et al.  Dysgerminoma of the ovary in association with XY gonadal dysgenesis. , 1983, European journal of obstetrics, gynecology, and reproductive biology.

[92]  M. Pike,et al.  Testicular germ cell tumor susceptibility associated with the UCK 2 locus on chromosome 1 q 23 , 2013 .

[93]  R. Butzow,et al.  Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors. , 2011, European journal of endocrinology.

[94]  E. Petricoin,et al.  Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  J. Dungan Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer , 2010 .

[96]  J. Thigpen,et al.  Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer , 2010 .

[97]  P. G. Knight,et al.  FOCUS ON TGF-? SIGNALLING: TGF-B SUPERFAMILY MEMBERS AND OVARIAN FOLLICLE DEVELOPMENT , 2006 .

[98]  E. Eugster,et al.  Premature thelarche and granulosa cell tumors: a search for FSH receptor and G5alpha activating mutations. , 2002, Journal of pediatric endocrinology & metabolism : JPEM.

[99]  A. Bradley,et al.  Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. , 1992, Nature.